US Pharma MarketingFTC accuses Martin Shkreli of violating lifetime pharma ban
The FTC and seven states ask a court to hold Martin Shkreli in contempt for allegedly violating his lifetime pharma industry ban. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Martin Shkreli is under FTC scrutiny once again.
The agency and seven states asked a New York federal court on Tuesday to hold Shkreli in contempt for allegedly violating a court-ordered lifetime ban from the ...
Source: Endpoints News